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Abstract
Purpose Demethylation of DNA through enzymes like LSD1 showed a crucial impact on different kind of cancers. Epigenetic 
modifications in cervical cancer are still not fully investigated nevertheless of high interest for a therapeutic use.
Methods Tumor samples of 250 cervical cancer patients were immunochemically stained and evaluated based on Immuno-
reactive Score. Results were statistically analyzed for clinical and pathological parameters.
Results Our patient collective showed a disadvantage for 10-year survival for patients with a strong expression of LSD1 
in the cytoplasm of cervical cancer cells. The results of the correlational analysis further revealed a negative correlation of 
LSD1 to G-protein coupled estrogen receptor (GPER).
Conclusions Epigenetic changes through enzymes like LSD1 may also be of interest for patients with cervical cancer. A 
combined therapy with other proteins relayed to cervical cancer like GPER might be of interest for future investigations.
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Background
Cervical cancer is with about 570,000 new cases in the year 
2018, the fourth most frequent cancer after breast, colorec-
tum and lung carcinoma in women worldwide. It represents 
about 6.6% of all female cancers. About 311,000 deaths 
occurred in 2018 caused of cervical cancer (World Health 
Organization [WHO (2020a)].About 90% of the cervical 
cancer deaths occur in low and middle- income countries. 
Prevention, early diagnosis, effective screening and treat-
ment programmes are essential to reduce the mortality 
rate of cervical cancer (World Health Organization [WHO 
(2020b)]. The two main histologic subtypes are squamous 
cell carcinoma with about 80% and adenocarcinoma with 
about 20% (Aviel-Ronen et al. 2016).
Cervical cancer is usually caused by persistent high-risk 
Human Papillomavirus (HR-HPV) infection, with human 
papillomavirus (HPV) being the most common sexually 
transmitted biological agent. About 85% of anogenital can-
cers in men and women are related to HPV infection (Leite 
et al. 2020).
HPV belongs to the Papillomaviridae family and is a 
circular, non-enveloped double-stranded DNA virus. Many 
subtypes have already been identified (Leite et al. 2020; 
Goodman 2015). There is a sub-classification of HPV infec-
tions of the genital tract in low risk, found mainly in geni-
tal warts-, and high risk HPV. HPV-6, HPV-11, HPV-40, 
HPV-42, HPV-43, HPV-44 and HPV-53 belongs to the low 
risk subtypes. The high risk types like HPV-16, HPV-18, 
HPV-31, HPV-33, HPV-35, HPV-39, HPV-45 and others are 
frequently associated with invasive cervical cancer (Munoz 
et al. 2003).
In the last years, the epigenetic processes in cancer cau-
sation, progression and treatment played an important role. 
Epigenetic abnormalities like the DNA methylation are lead-
ing candidates for the diagnosis, prognosis and the devel-
opment of markers for cancer detection (Baylin and Jones 
2011). Epigenetic therapy like histone modification was 
already successful in treating hematopoietic malignancies 
(Liu et al. 2017).
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LSD1 (Lysine Specific Demethylase 1) works as a histone 
demethylase and as a transcriptional corepressor by dem-
ethylating histone H3 lysine 4, which is associated to active 
gene transcription (Shi et al. 2004).
LSD1 plays a role in cellular processes like cell prolifera-
tion (Lan et al. 2008) and stem cell pluripotent regulation 
(Whyte et al. 2012) and a dysregulation was associated with 
human cancer development (Amente et al. 2013; Gu et al. 
2020).
Overexpression of LSD1 was already found in several 
types of solid tumors like prostate cancer, bladder cancer, 
neuroblastoma, lung cancer, sarcomas, colorectal or hepato-
carcinomas (Amente et al. 2013; Hayami et al. 2011). Ele-
vated LSD1 expression correlates with tumor progression 
and negative clinical outcomes (Liu et al. 2017). An inhi-
bition or knock down of LSD1 was found to suppress cell 
growth, invasion and migration in solid tumors like non-
small cell lung cancer (Lv et al. 2012). For some cancer 
types, LSD1 has also been proposed as a biomarker (Amente 
et al. 2013).
Regarding the high levels of LSD1 which is associated 
with tumor progression, in the last years this protein was 
an interesting target for drug discovery; it was proposed 
that epigenetic drugs targeting LSD1 could be used for the 
therapy of cancer (Amente et al. 2013).
To investigate the role of LSD1 in cervical cancer more 
studies are needed, so the aim of this study is to identify 
epigenetic modifications in cervical cancer to improve future 
knowledge for diagnostics and therapy of cervical cancer.
Methods
Patients
Our study analysed 250 paraffin embedded cervical can-
cer samples from patients of the Department of Obstetrics 
and Gynaecology of the Ludwig-Maximilians University 
of Munich (LMU) between 1993 and 2002. Our samples 
included only the two most frequent histological subtypes, 
squamous cell carcinoma and adenocarcinoma. Other sub-
types were not chosen for their relatively small number of 
cases. Table 1 presents an overview of clinical and patho-
logical parameters from our specimens.
Immunohistochemistry
For analysing the expression of LSD1 in our study group 
we performed an immunohistochemical staining. In the 
first step in this process paraffin embedded and formalin 
fixed tumor samples of 3 µm were prepared on microscope 
slides. Our samples were first deparaffined with Roticlear 
and then washed in 100% ethanol. With the next step, we 
blocked endogenous peroxidase with 3% methanol/H2O2 
followed by a treatment in descending alcohol levels for 
rehydration. The samples were washed in distilled water 
and then cooked in a pressure cooker covered in a sodium-
citrate buffer (pH = 6.0) for 5 min by a maximum heat of 
100 °C. Afterwards the samples were cleaned again in 
distilled water before washing the slides in PBS-buffer. 
For a valid staining, we first treated our tumor samples 
with a blocking solution to keep unspecific hydrophobic 
binding as low as possible and then incubated our slides 
Table 1  Clinical and pathological parameters for age, pN-status, pT-




 ≤ 50 years 141/250 56.4


























 ≥ 1 58/250 23.2
 N/A 2/250 0.8
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with the primary LSD1 antibody (Anti-LSD1). After an 
incubation time of 16 h by 4 °C, our slides were washed 
in PBS-buffer, treated with post-block solution and then 
covered in HRP-polymer. After washing the slides again in 
PBS-buffer the tumor samples were stained with DAB and 
directly counterstained with Haemalaun. To complete the 
staining process our samples were dehydrogenated again 
in a rising alcohol series.
To determine whether a patient had a low or high 
expression of LSD1 the Immunoreactive Score (IRS) was 
used and each tumor sample was rated from 0 (no expres-
sion) to 12 (very high expression). Like established, IRS 
was calculated from intensity (0 = not stained; 1 = low 
intensity; 2 = moderate intensity, 3 = high intensity) mul-
tiplied by the percentage rate of stained cells (0 = not 
stained; 1 = 1–10%; 2 = 11–50%; 3 = 51–80%; 4 ≥ 81%).
Statistics
To analyse our collected data, we created a database using 
IBM Statistics version 25 (Amrok, NY, USA). For all 
significant results, p was required to be < 0.05. Median 
expression for various clinical and pathological parameters 
was studied. Cumulative survival time, cox regression and 
correlations on this patient group were calculated.
Results
LSD1 staining in cervical cancer
The median cytoplasmic IRS of the staining was 8 com-
pared with a median IRS of 12 in the nucleus. 1.8% of the 
cases showed no expression in the cytoplasm and 0.5% no 
detectable staining in the nucleus. 28.0% showed a low 
expression in the cytoplasm while 72.0% presented a high 
expression in the cytoplasm. In comparison, 6.6% pre-
sented a low and 93.4% a high expression in the nucleus. 
The median cytoplasmic IRS for squamous carcinoma 
and for adenocarcinoma was 8 and the nuclear median 
IRS was 12 for both histological subtypes. Depending on 
tumour grading appeared a median cytoplasmic IRS of 9 
for grading G1 and a median IRS of 8 for grading G2 and 
G3 tumours (Fig. 1) while median nuclear IRS was 12 
for each grading. According to tumour size each t-status 
showed a median IRS of 8 in cytoplasm and 12 nuclear 
for T1 and T2. Tumour size T3/4 had a median IRS of 8, 
both for nucleus and cytoplasm. Patients with (N +) or 
without (N-) lymph node metastasis had a median IRS of 
8 in the cytoplasm and a nuclear IRS of 12. Cytoplasmatic 
median IRS for FIGO I-III tumours was 8 while FIGO IV 
tumours showed a median IRS of 4 in cytoplasm. All cases 
from FIGO I to FIGO IV presented a median IRS of 12 
in the cell nucleus. Table 2 illustrates the median IRS for 
the expression of LSD1 for histological subtype, grading, 
T-status, N-status and FIGO classification separately in 
cytoplasm and nucleus.
Correlation analyses of LSD1 staining with other 
parameters in cervical cancer
For further investigation of LSD1 as a prognostic factor in 
cervical cancer, we analysed our data bank for correlations 
of LSD1 expression and other parameters. There was a sig-
nificantly negative correlation between LSD1 expression and 
GPER (p = 0.009).
Correlation of LSD1 expression in cervical cancer 
and survival
With a median age of 47 years, we recorded patients in a 
range from 20 to 83 years and a median survival time of 
100 months. A very strong IRS (IRS = 12) of the cytoplasm 
for LSD1 showed a disadvantage for 10-year overall survival 
(p = 0.032). Within 120 months, if an IRS of 12 was seen 
10% more women died compared to women with a lower 
IRS. A high LSD1 IRS-score was related with a 9.4 months 
shorter median survival time (Fig. 2).
Cox regression
In order to evaluate independent histological parameters 
for survival in our specimens we used a multivariate cox-
regression analysis. As presented in Table 3, histological 
subtype (p = 0.001), pN-status (p = 0.009) and expression 
of LSD1 (p = 0.037) were independent prognostic factors 
for overall survival.
Discussion
This study was designed with the aim of assessing expres-
sion of LSD1, an enzyme responsible for DNA demethyla-
tion and subsequent epigenetic modifications to develop 
further knowledge in the challenging task of clinical diag-
nostics and therapy of cervical cancer. The current study 
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found that a high expression of LSD1 in cervical cancer 
tissue was a significant disadvantage in 10-year-survival in 
our patient collective. It is also interesting to note that we 
found a significant negative correlation of LSD1 expression 
to G-Protein Coupled Estrogen Receptor (GPER).
Many epigenetic mechanisms have been discovered to 
modify gene expression leading this machinery to play a 
fundamental role in biological diversity of cells (Taby 
and Issa 2010). In the same way, epigenetic aberrations 
are a central part of cancer development including 
DNA methylation (Baylin and Jones 2011). LSD1 is a 
histone lysine demethylase and functions as an important 
transcriptional corepressor by demethylating H3K4me2/
me1 and H3K9me2/me1 (Shi et al. 2004). Prior studies have 
already described that dysregulation of LSD1 can influence 
cancer development: Overexpression of LSD1 correlates 
with poor prognosis in various cancer types like bladder 
cancer (Hayami et al. 2011), colon cancer (Jie et al. 2013) 
or hepatocellular carcinoma (Kim et al. 2019). Our result are 
contrary to a previous study by Liu et al. (2017) who could 
not find a statistically significant difference in overall nor in 
tumor free survival for cervical cancer patients with a high 
or low expression of LSD1 (Liu et al. 2017). However, our 
findings instead broadly support the work of previous studies 
Fig. 1  Illustration of immunohistochemical staining results for grad-
ing. Stained cervical cancer samples with a median cytoplasmic IRS 
for grading G1 of 9 (a), G2 of 8 (b) and G3 of 8 (c). d presents box-
plots with median IRS of 9 for grading G1 and a median IRS of 8 for 
grading G2 and G3 in cytoplasm. The asterisk (*) indicates signifi-
cant lower expression of LSD1 in patients with higher Grading
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related signaling (Xu et al. 2019). During the last years, 
estrogen was continuously discovered to be deeply involved 
in cancer progression in different kinds of cancers (Chan 
et al. 2017; Hsu et al. 2017; Yu et al. 2017). Estrogen signals 
are suggested to play a crucial role in development of cervi-
cal cancer (Zhang et al. 2015). Thus, non-genomic estrogen 
effects performed by GPER has become an interesting sub-
ject to study (Xu et al. 2019). Our study group described in 
2014 GPER as a positive prognostic factor in ovarian can-
cer with reduced overall survival for patients with a strong 
GPER intensity (Heublein et al. 2014). In accordance with 
the previous results another study from our group confirmed 
GPER to be associated with improved recurrence-free and 
overall survival also in cervical cancer (Friese et al. 2018). 
A possible explanation for this negative correlation of LSD1 
and GPER might be that tumor suppressor inactivation origi-
nates mainly in genetic and epigenetic mechanisms including 
methylation of the promoter to supress the gene’s transcrip-
tion (Osborne et al. 2004; Payne and Kemp 2005). In accord-
ance with this, another study has demonstrated that GPER 
expression was influenced through methylation and dem-
ethylation of the promoter in breast cancer patients (Weis-
senborn et al. 2014). It is therefore likely that a connection 
exists between both proteins—LSD1 and GPER. However, 
an explanation for this finding remains unanswered at pre-
sent and can only be hypothesized. Nevertheless, a combined 
treatment of LSD1 inhibitors with other therapeutic targets 
(Fang et al. 2019), already supposed by Fang et al. (2019), 
may be also of interest for future investigations of LSD1 and 
GPER in cervical cancer.
The purpose of the current study was to describe 
epigenetic modifications in cervical cancer. This study 
has shown that very strong expression of cytoplasmic 
LSD1 showed a disadvantage in 10-year overall survival 
(p = 0.032) in our patient collective. The second major 
finding was a significant negative correlation between 
LSD1 expression and GPER (p = 0.009). Overall, this 
study strengthens the idea that epigenetic modifications 
are also meaningful in cervical cancer and in particular 
LSD1 may play an important role with a negative 
influence on patients’ survival. Furthermore, this study 
has raised important questions about connections of 
LSD1 and GPER. Many studies have shown that GPER 
can mediate multiple signaling pathways (Xu et al. 2019) 
and also LSD1 interacts together with many proteins 
(Fang et al. 2019). Future studies on LSD1 and GPER 
are therefore recommended to increase more knowledge 
of these two proteins as highly interesting therapeutic 
targets.
Table 2  Immunohistochemical results for LSD1 staining. Illustra-
tion of median IRS for expression of LSD1 for histological subtype, 
grading, T-status, N-status and FIGO classification separately in cyto-
plasm and nucleus
Cytoplasm Nucleus
Median IRS 8 12
Expression
 No expression 1.8% 0.5%
 IRS 1–5 28.0% 6.6%
 IRS 6–12 72.0% 93.4%
Histological subtype (IRS)


















about LSD1 linking an overexpression of cytoplasmic LSD1 
to a disadvantage in 10-year survival also for patients with 
cervical cancer. Despite that the previous mentioned study 
found that ectopic expression of LSD1 in cervical cancer 
cells increases invasion and metastasis (Liu et al. 2017) and 
confirms the picture of LSD1 as a negative factor in cervical 
cancer. Besides its specific demethylase activity, LSD1 has 
been increasingly described to play a role in a wide range of 
cellular processes (Gu et al. 2020) like cell differentiation 
(Lan et  al. 2008) or migration and invasion of cancer 
(Ambrosio et al. 2017). It is therefore likely that LSD1 will 
become an interesting target for anticancer treatment (Yang 
et al. 2018).
Another important finding was a negative correlation of 
LSD1 expression to GPER expression, a seven-transmem-
brane-domain receptor that mediates non-genomic estrogen 
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tological subtype (p = 0.001), pN-status (p = 0.009) and expression of 







CI of Exp 
(B)
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